Maulik Patel1, Sadakatsu Ikeda2, Susan R Pilat3, Razelle Kurzrock4. 1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California-San Diego, La Jolla. 2. Cancer Center, Tokyo Medical and Dental University, Tokyo, Japan. 3. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston. 4. Center for Personalized Cancer Therapy, Division of Hematology/Oncology, Department of Medicine, University of California-San Diego, La Jolla.
Abstract
Importance: Castleman disease (CD) is an ultrarare, interleukin-6 (IL-6)-driven lymphoproliferative disorder whose underlying molecular alterations are unknown. Siltuximab (anti-IL-6 antibody) is approved for treatment of this disease. To our knowledge, genomic sequencing of CD has not been reported. Objective: To investigate and identify molecular aberration(s) that help explain the exceptional response to siltuximab in a patient with cutaneous CD. Design, Setting, and Participants: This case study examines data from comprehensive genomic profiling (using targeted next-generation sequencing) of tissue from a patient with cutaneous CD who demonstrated an exceptional response to siltuximab treated at a National Cancer Institute-designated Comprehensive Cancer Center. Interventions: Intravenous siltuximab 12 mg/kg every 3 weeks. Tissue from the patient was interrogated by next-generation sequencing (405 genes). Serum was evaluated for IL-6 levels by enzyme-linked immunoassay. Main Outcomes and Measures: Identification of pretreatment serum IL-6 levels and somatic variants that may explain the exceptional response to siltuximab in this patient with cutaneous CD. Results: Patient pretreatment serum IL-6 levels were normal. Treatment with siltuximab resulted in a complete response lasting 7 years. Next-generation sequencing demonstrated a JAK1V310I missense mutation. Janus Kinase 1 (JAK1) is a crucial signaling component of the IL-6/IL-6 receptor/gp130 machinery. JAK1V310I may induce a conformation change with functional activation effect leading to enhanced sensitivity to the IL-6 ligand. Conclusions and Relevance: Our observations suggest that a JAK1 alteration may explain the underlying biology of a patient's cutaneous CD, as well as the patient's exceptional response to siltuximab.
Importance: Castleman disease (CD) is an ultrarare, interleukin-6 (IL-6)-driven lymphoproliferative disorder whose underlying molecular alterations are unknown. Siltuximab (anti-IL-6 antibody) is approved for treatment of this disease. To our knowledge, genomic sequencing of CD has not been reported. Objective: To investigate and identify molecular aberration(s) that help explain the exceptional response to siltuximab in a patient with cutaneous CD. Design, Setting, and Participants: This case study examines data from comprehensive genomic profiling (using targeted next-generation sequencing) of tissue from a patient with cutaneous CD who demonstrated an exceptional response to siltuximab treated at a National Cancer Institute-designated Comprehensive Cancer Center. Interventions: Intravenous siltuximab 12 mg/kg every 3 weeks. Tissue from the patient was interrogated by next-generation sequencing (405 genes). Serum was evaluated for IL-6 levels by enzyme-linked immunoassay. Main Outcomes and Measures: Identification of pretreatment serum IL-6 levels and somatic variants that may explain the exceptional response to siltuximab in this patient with cutaneous CD. Results:Patient pretreatment serum IL-6 levels were normal. Treatment with siltuximab resulted in a complete response lasting 7 years. Next-generation sequencing demonstrated a JAK1V310I missense mutation. Janus Kinase 1 (JAK1) is a crucial signaling component of the IL-6/IL-6 receptor/gp130 machinery. JAK1V310I may induce a conformation change with functional activation effect leading to enhanced sensitivity to the IL-6 ligand. Conclusions and Relevance: Our observations suggest that a JAK1 alteration may explain the underlying biology of a patient's cutaneous CD, as well as the patient's exceptional response to siltuximab.
Authors: Y J Zhou; M Chen; N A Cusack; L H Kimmel; K S Magnuson; J G Boyd; W Lin; J L Roberts; A Lengi; R H Buckley; R L Geahlen; F Candotti; M Gadina; P S Changelian; J J O'Shea Journal: Mol Cell Date: 2001-11 Impact factor: 17.970
Authors: Razelle Kurzrock; Peter M Voorhees; Corey Casper; Richard R Furman; Luis Fayad; Sagar Lonial; Hossein Borghaei; Sundar Jagannath; Lubomir Sokol; Saad Z Usmani; Helgi van de Velde; Xiang Qin; Thomas A Puchalski; Brett Hall; Manjula Reddy; Ming Qi; Frits van Rhee Journal: Clin Cancer Res Date: 2013-05-09 Impact factor: 12.531
Authors: Patrick J Lupardus; Georgios Skiniotis; Amanda J Rice; Christoph Thomas; Suzanne Fischer; Thomas Walz; K Christopher Garcia Journal: Structure Date: 2011-01-12 Impact factor: 5.006
Authors: M B Leger-Ravet; M Peuchmaur; O Devergne; J Audouin; M Raphael; J Van Damme; P Galanaud; J Diebold; D Emilie Journal: Blood Date: 1991-12-01 Impact factor: 22.113
Authors: Frits van Rhee; Corey Casper; Peter M Voorhees; Luis E Fayad; Helgi van de Velde; Jessica Vermeulen; Xiang Qin; Ming Qi; Brenda Tromp; Razelle Kurzrock Journal: Oncotarget Date: 2015-10-06
Authors: Lori I Robins; Erika K Keim; Deborah B Robins; John S Edgar; John S Meschke; Philip R Gafken; Jeffrey F Williams Journal: ACS Omega Date: 2021-12-14